| Literature DB >> 33101439 |
Yinhe Deng1, Quanjiang Li1, Menglin Li1, Tiantian Han1, Guixian Li1, Qiong Liu2.
Abstract
BACKGROUND: Sang-Xing-Zhi-Ke-Fang (SXZKF) demonstrates good therapeutic effect against pharyngitis. Nevertheless, the pharmacological mechanism underlying its effectiveness is still unclear.Entities:
Year: 2020 PMID: 33101439 PMCID: PMC7576344 DOI: 10.1155/2020/2421916
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Workflow of this study.
Figure 2387 overlapping genes between SXZKF compounds-related targets and pharyngitis-related targets from GeneCards and CTD.
Figure 3H-C-T network. Yellow nodes represent the herbs of SXZKF, green nodes represent the bioactive compounds of SXZKF, and pink nodes represent the potential targets of SXZKF against pharyngitis.
Figure 4Screening of core targets by analyzing topological features of the PPI network. Red nodes represent the core targets.
Detailed information of 63 core targets.
| NO. | Target name | Degree centrality | Betweenness centrality | Closeness centrality |
|---|---|---|---|---|
| 1 | ALB | 132 | 0.10194051 | 0.57963875 |
| 2 | SREBF1 | 101 | 0.04648343 | 0.54058193 |
| 3 | APOB | 88 | 0.02798912 | 0.52373887 |
| 4 | APOE | 87 | 0.03066411 | 0.52765321 |
| 5 | PPAR | 84 | 0.02496889 | 0.53082707 |
| 6 | MAPK3 | 82 | 0.03803816 | 0.52923538 |
| 7 | HMGCR | 79 | 0.02839721 | 0.51911765 |
| 8 | EGF | 77 | 0.0326961 | 0.51683748 |
| 9 | LDLR | 74 | 0.01786479 | 0.5 |
| 10 | FASN | 74 | 0.01620772 | 0.502849 |
| 11 | PPARA | 74 | 0.01758367 | 0.5130814 |
| 12 | PTGS2 | 73 | 0.03636725 | 0.50573066 |
| 13 | SREBF2 | 72 | 0.02642683 | 0.4862259 |
| 14 | APP | 68 | 0.02026671 | 0.50500715 |
| 15 | LEP | 67 | 0.01366234 | 0.50864553 |
| 16 | ABCA1 | 66 | 0.02050839 | 0.49509116 |
| 17 | SCD | 66 | 0.01940855 | 0.48891967 |
| 18 | APOA1 | 65 | 0.0104694 | 0.48891967 |
| 19 | CAT | 59 | 0.0231604 | 0.50070922 |
| 20 | ADIPOQ | 59 | 0.01236963 | 0.49788434 |
| 21 | CYP3A4 | 59 | 0.01670894 | 0.48356164 |
| 22 | ESR1 | 58 | 0.0240653 | 0.49509116 |
| 23 | DGAT1 | 54 | 0.00895186 | 0.47446237 |
| 24 | CYP2B6 | 53 | 0.01261496 | 0.48422497 |
| 25 | APOC3 | 51 | 0.00521994 | 0.45844156 |
| 26 | ACACA | 51 | 0.0040295 | 0.47638327 |
| 27 | CREB1 | 51 | 0.01442992 | 0.49164345 |
| 28 | SIRT1 | 50 | 0.01736748 | 0.49301676 |
| 29 | MAPK14 | 48 | 0.00877424 | 0.47702703 |
| 30 | FABP1 | 48 | 0.01145724 | 0.46693122 |
| 31 | CAV1 | 48 | 0.01458166 | 0.48092643 |
| 32 | SQLE | 47 | 0.00778386 | 0.44853875 |
| 33 | AGT | 47 | 0.00760543 | 0.47510094 |
| 34 | CLU | 47 | 0.00773464 | 0.45844156 |
| 35 | LIPE | 47 | 0.00794991 | 0.47638327 |
| 36 | FADS1 | 47 | 0.00692009 | 0.45607235 |
| 37 | LIPC | 46 | 0.00999712 | 0.44968153 |
| 38 | CYP2E1 | 46 | 0.01342474 | 0.4738255 |
| 39 | IL4 | 45 | 0.00870765 | 0.47192513 |
| 40 | ACOX1 | 45 | 0.0035187 | 0.45784695 |
| 41 | HMGCS1 | 44 | 0.00325402 | 0.44853875 |
| 42 | ACLY | 44 | 0.01071917 | 0.46083551 |
| 43 | CYP19A1 | 44 | 0.01030837 | 0.47255689 |
| 44 | CYP2C9 | 44 | 0.00700349 | 0.46754967 |
| 45 | SCARB1 | 44 | 0.00915057 | 0.47003995 |
| 46 | FDFT1 | 43 | 0.00425437 | 0.45140665 |
| 47 | DGAT2 | 43 | 0.00166345 | 0.44291092 |
| 48 | APOA4 | 43 | 0.00578781 | 0.45314506 |
| 49 | CD44 | 43 | 0.01055526 | 0.46816976 |
| 50 | CYP51A1 | 41 | 0.00425467 | 0.44180225 |
| 51 | HSD3B1 | 41 | 0.00690686 | 0.44180225 |
| 52 | DHCR7 | 41 | 0.00378824 | 0.42891859 |
| 53 | PON1 | 41 | 0.00478681 | 0.46693122 |
| 54 | LSS | 40 | 0.00646986 | 0.44570707 |
| 55 | ACE | 40 | 0.00407366 | 0.47255689 |
| 56 | ABCG2 | 40 | 0.02206365 | 0.46816976 |
| 57 | F2 | 39 | 0.00736964 | 0.47319035 |
| 58 | KRAS | 39 | 0.00749875 | 0.46143791 |
| 59 | LCAT | 39 | 0.00395196 | 0.46204188 |
| 60 | NR3C1 | 39 | 0.00692536 | 0.47003995 |
| 61 | FABP4 | 38 | 0.0045635 | 0.44796954 |
| 62 | ABCB1 | 38 | 0.01106088 | 0.46693122 |
| 63 | HNF4A | 38 | 0.01122196 | 0.47574124 |
Figure 5Bubble chart of top 20 signaling pathways linked to SXZKF against pharyngitis. Bubble size represented the number of genes enriched in this pathway, color depth represented the P value, and rich factor represented the ratio of the enriched targets in the pathway to the total number of targets in the pathway.
Functions of 387 target genes based on KEGG pathway analysis.
| Term | Number of pathway gene |
|
|---|---|---|
| Linoleic acid metabolism | CYP3A4, CYP2J2, CYP2C19, CYP2C9, CYP2C8, CYP2E1, CYP1A2, PLA2G4A, PLA2G1B, PLA2G2A, PLA2G6, PLA2G3, PLA2G4C, PLA2G5 | 1.20 |
| VEGF signaling pathway | PIK3CG, PRKCA, PTGS2, MAPKAPK2, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, MAPK3, RAC1, PLA2G4C, AKT2 | 2.69 |
| Serotonergic synapse | PRKCA, PLA2G4A, APP, CYP2J2, KRAS, CYP2C19, PTGS2, CYP2C9, CYP2C8, CYP2D6, MAPK3, PTGS1, ALOX12B, PRKACA, ALOX5, PLA2G4C, PRKCB | 4.54 |
| Fc epsilon RI signaling pathway | IL4, PIK3CG, PRKCA, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, MAPK3, RAC1, PLA2G4C, SYK, AKT2 | 8.83 |
| Alpha-linolenic acid metabolism | ACOX1, PLA2G4A, PLA2G2A, PLA2G1B, PLA2G6, PLA2G4C, PLA2G3, PLA2G5 | 3.08 |
| Pancreatic cancer | PIK3CG, KRAS, RAC2, TGFBR1, MAPK3, TGFBR2, RAC1, NFKB1, SMAD2, EGF, TGFB1, AKT2 | 3.17 |
| Chagas disease (American trypanosomiasis) | PIK3CG, CCL3, TGFBR1, TGFBR2, NFKBIA, NFKB1, SMAD2, BDKRB2, CALR, TGFB1, ACE, MAPK14, MAPK3, FAS, AKT2 | 3.98 |
| Metabolism of xenobiotics by cytochrome P450 | CYP3A4, CYP2A13, CYP3A5, CYP1B1, CYP1A1, CYP2B6, CYP2C9, CYP2D6, CYP2A6, CYP2E1, CYP1A2, AKR1C1 | 1.09 |
| Sphingolipid signaling pathway | PRKCA, PIK3CG, SGMS2, CERS5, NFKB1, SGMS1, BDKRB2, PRKCB, KRAS, RAC2, MAPK14, MAPK3, RAC1, ABCC1, AKT2 | 1.93 |
| Chemical carcinogenesis | CYP3A4, CYP2A13, CYP3A5, CYP1B1, CYP1A1, CYP2C19, PTGS2, CYP2C9, CYP2C8, CYP2A6, CYP2E1, CYP1A2 | 2.22 |
| Ras signaling pathway | PRKCA, PIK3CG, FGFR4, CSF1, NFKB1, PRKCB, PLA2G4A, KRAS, RAC2, RAC1, MAPK3, PLA2G1B, PLA2G2A, PLA2G6, PRKACA, FGF1, PLA2G3, PLA2G4C, EGF, PLA2G5, AKT2 | 4.17 |
| Osteoclast differentiation | PIK3CG, NCF2, TGFBR1, CSF1, CREB1, PPARG (PPAR | 4.83 |
| Colorectal cancer | PIK3CG, KRAS, RAC2, TGFBR1, MAPK3, TGFBR2, RAC1, SMAD2, TGFB1, AKT2 | 5.51 |
| FoxO signaling pathway | PIK3CG, TGFBR1, TGFBR2, SMAD2, SIRT1, TGFB1, G6PC, KRAS, MAPK14, MAPK3, PRKAA1, CAT, PRKAA2, EGF, AKT2 | 6.08 |
| Retinol metabolism | CYP3A4, CYP3A5, DGAT1, CYP1A1, CYP2B6, CYP2C9, CYP2C8, HSD17B6, CYP2A6, CYP1A2 | 7.00 |
| MAPK signaling pathway | PRKCA, FGFR4, TGFBR1, TGFBR2, NFKB1, HSPA1A, HSPA1B, MAPKAPK2, TGFB1, PRKCB, PLA2G4A, KRAS, RAC2, MAPK14, RAC1, MAPK3, PRKACA, FAS, FGF1, PLA2G4C, EGF, AKT2 | 7.04 |
| Drug metabolism-cytochrome P450 | CYP3A4, CYP3A5, CYP2C19, CYP2B6, CYP2C9, CYP2C8, CYP2D6, CYP2A6, CYP2E1, CYP1A2 | 0.001095 |
| B Cell receptor signaling pathway | PIK3CG, KRAS, RAC2, MAPK3, RAC1, CD81, NFKBIA, NFKB1, AKT2, SYK | 0.001218 |
| Hepatitis C | PIK3CG, PPARA, LDLR, RXRA, NFKBIA, NFKB1, KRAS, MAPK14, MAPK3, CD81, SCARB1, EGF, AKT2, NR1H3 | 0.001755 |
| Influenza A | PRKCA, PIK3CG, IL18, FDPS, NFKBIA, NLRX1, HSPA1A, NFKB1, HSPA1B, NLRP3, PRKCB, MAPK14, MAPK3, PYCARD, FAS, AKT2 | 0.002805 |
Figure 6C-T-P network. Yellow nodes represent the bioactive compounds, red nodes represent the key pathways, and purple nodes represent the target genes.
Figure 7Chemical structures of key compounds. (a) Arachidonic acid. (b) Quercetin. (c) Kaempferol. (d) Eicosapentaenoic acid. (e) Luteolin.